Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3549492 for Weight Management in Adults With Obesity or Overweight
NCT06683508Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naperiglipron in obesity, Overweight, sponsored by Eli Lilly and Company. Started Nov 2024; status: completed.
02
Drugs
naperiglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06683508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683508.